Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Johnson and Johnson
Johnson and Johnson
Activities:
Research & Development
Medical Devices
Pharmaceutical
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Regulatory
FDA grants approval for Johnson & Johnson's antibody for treatment of myeloma
Johnson & Johnson have received accelerated approval of TALVEY, a first-in-class bispecific antibody. TALVEY is a bispecific T-cell engaging antibody that binds to the CD3 receptor
Manufacturing
First-line treatment for patients with metastatic castration-resistant prostate cancer
A company has submitted an NDA for niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT)
Research & Development
F-star Therapeutics announces license agreement with Janssen
The agreement grants Janssen an exclusive license to research, develop, and commercialise bispecific antibodies directed to its therapeutic targets using F-star’s proprietary Fcab and mAb2 platforms
Research & Development
BioMed X and Janssen R&D announce two research groups
The groups will explore research related to autoimmunity and drug delivery
Ingredients
Therapeutic: nipocalimab for myasthenia gravis
The chronic autoimmune disease, myasthenia gravis, affects the skeletal muscles responsible for eye movements, breathing and motion
Research & Development
BioMed X begins research project for oral therapeutics delivery
The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation
Manufacturing
GEA continuous plant lands ISPE FOYA for Janssen
GEA helps Janssen Belgium to redefine the future pharmaceutical supply chain with ConsiGma 4.0 continuous manufacturing solutions
Subscribe now